Today at #ESMO26 in Madrid, we shared new Phase 1 data on our investigational FRα-targeting antibody-drug conjugate in heavily pretreated patients with platinum-resistant ovarian cancer. The results reinforce our confidence in the potential of this approach to help expand treatment options for patients with ovarian cancer. Read the key data highlights here: ir.zymeworks.com/news-releas… #OvarianCancer #ADC

Zymeworks has entered into an exclusive global license and collaboration agreement with @Roche for ZW209, a DLL3-targeting trispecific T cell engager. Under the agreement, Zymeworks is eligible to receive a $55 million upfront payment, a $40 million payment upon initiation of the Phase 1b trial, and up to $718 million in additional development, commercial and sales-based milestones, plus tiered royalties on future global net sales. Zymeworks will conduct the Phase 1a monotherapy trial in collaboration with Roche, which will fund the trial and lead subsequent global development and commercialization. The agreement reflects Zymeworks’ strategy of advancing innovative programs through its R&D engine and partnering selected assets to share development risk while retaining meaningful participation in future success. Read the full announcement: lnkd.in/garA3Vi7 Zymeworks management will host a conference call on October 27 at 8:30 am ET. #Oncology #RocheInnovation #pRED

We’re pleased to welcome Suzanne Monahan to Zymeworks as Senior Vice President, Commercial and General Manager, Theravance Biopharma. Suzanne brings more than 20 years of commercial leadership experience across the pharmaceutical and medical device industries, with expertise in product launches, market access, strategic partnerships and respiratory markets. In her new role, Suzanne will lead Zymeworks’ commercial strategy and execution for YUPELRI® (revefenacin), the first and only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for the maintenance treatment of COPD. Read today's announcement: ir.zymeworks.com/news-releas…

Zymeworks will report its third quarter 2026 financial results on November 9, and participate in several investor conferences throughout November, including the Wolfe Research, Stifel, Truist Securities, and Jefferies Healthcare Conferences. We look forward to engaging with the investment community and sharing updates on our business and strategic priorities. Read today’s announcement: ir.zymeworks.com/news-releas…

Giving back to the communities where we live and work is an important part of who we are at Zymeworks. This week, employees across our hubs in Vancouver, Bellevue, New York City, Dublin, and Singapore came together for our annual all-staff giving-back event. Through hands-on activities and community initiatives, we helped bring support and a little joy to more than 1,000 children receiving care in hospitals, as well as their families and caregivers. We’re proud of what we accomplished together and grateful to everyone who gave their time and energy to make the day such a success.

We’re heading into a busy fall conference season, with Zymeworks researchers presenting new clinical and preclinical data across multiple medical conferences. At #ESMO26 on October 24, we’ll share new clinical results from our Phase 1 randomized dose optimization study of ZW191 in heavily pretreated patients with platinum-resistant ovarian cancer. At #SITC26, we’ll present new preclinical data on a novel approach designed to target IL-7 to tumor-specific T cells. At #PEGSEurope, we’ll showcase work across our next-generation multispecific programs and cytokine engineering. Learn more here: lnkd.in/g8iDK7bX

Today, on the National Day for Truth and Reconciliation and Orange Shirt Day, we pause to remember the children who never came home and honour Survivors, their families and communities. We recognize that reconciliation is an ongoing journey, and an opportunity to learn, reflect and build a better path forward together. We encourage everyone to take time to learn more about the history and significance of this day through resources from the National Centre for Truth and Reconciliation, today and throughout the year. Learn more: nctr.ca #NationalDayforTruthandReconciliation #OrangeShirtDay

As Ovarian Cancer Awareness Month comes to a close, the need for awareness and support continues on. For patients, caregivers and loved ones navigating a gynecologic cancer diagnosis, finding the right information and support can make a meaningful difference. Resources are available to help with everything from managing a diagnosis and finding support to navigating financial assistance and other challenges along the way. Explore resources for patients and caregivers from the Ovarian Cancer Research Alliance: ocrahope.org/resources-suppo… #OvarianCancer #CancerAwareness #Oncology

We’ve completed the acquisition of Theravance Biopharma, advancing our strategy to build a productive R&D company with a growing portfolio of revenue-generating assets and diversified, durable cash flows. We’re also pleased to welcome Stuart Knight as EVP & CIO and Jesse Fecker, Ph.D., J.D., as VP, Intellectual Property. Read the full announcement: ir.zymeworks.com/news-releas… Join our conference call today at 8:30 am ET: edge.media-server.com/mmc/p/…

Our Zymeworks team came together at Stanley Park this past weekend to run, walk and support @TerryFoxCanada's vision of a world without cancer. The Terry Fox Run continues to bring people together across Canada to raise funds for cancer research and carry forward Terry’s incredible legacy. A huge congratulations to our team on an amazing fundraising effort, and thank you to everyone who ran, walked, donated, fundraised or cheered us on. Well done, Team Zymeworks! #TerryFoxRun #CancerResearch

Today, we announced the completion of our acquisition of Theravance Biopharma. With the transaction now complete, Theravance Biopharma is officially part of Zymeworks, marking an important step in our strategy to build a diversified, revenue-generating biotechnology company combining innovative R&D with growing commercial and royalty-based cash flows. We’ll host a conference call for investors and the general public on Monday, September 28 at 8:30 am ET to discuss the final transaction details. Learn more and access the webcast: ir.zymeworks.com/news-releas…

We’re pleased to share that our FRα-targeting antibody-drug conjugate (#ADC) has been selected for a Rapid Oral Presentation at the 2026 @myESMO Congress in Madrid. The presentation will feature new clinical results from our Phase 1 randomized dose optimization study in heavily pretreated patients with platinum-resistant ovarian cancer (PROC). Title: Randomized dose optimization of ZW191 in heavily pretreated patients with platinum-resistant ovarian cancer Date/Time: Saturday, October 24 at 8:30–10:00 am CET View this year's program: cslide.ctimeetingtech.com/es… We look forward to sharing these findings with the oncology community at #ESMO26! #OvarianCancer #CancerResearch

September is Ovarian Awareness Month — an opportunity to recognize the patients and families affected by these cancers and highlight the importance of continued research and innovation. We’re proud to share a recently published study from our scientists exploring the preclinical profile of our folate receptor alpha (FRα)-targeting antibody-drug conjugate. The research demonstrated promising anti-tumor activity across multiple tumor models, including ovarian and endometrial cancers, and provided insights into the differentiated properties of the antibody and payload. Read the publication: lnkd.in/giA5kXAV #OvarianCancer #ADC #CancerResearch

We’re pleased to share that Bijal Desai, SVP, Finance at Zymeworks, will participate in a panel discussion at Informa’s Life Sciences Product Launch Summit next week. Bijal will join industry leaders for “Optimizing Gross-to-Net (GTN) and Financial Planning for Launch Success,” exploring the role of financial planning in supporting successful product launches. Tuesday, September 22 10:45–11:15 am ET Learn more about the event: informaconnect.com/product-l… #LifeSciences #Biotech #Finance

This week Zymeworks’ management team will participate in two healthcare investor conferences in New York: Morgan Stanley Healthcare Conference — September 14 Fireside chat at 4:50 pm ET H.C. Wainwright Annual Global Investment Conference — September 15 Fireside chat at 3:30 pm ET Learn more: ir.zymeworks.com/events-and-…

Zymeworks’ management team will participate in two healthcare investor conferences this week: Wells Fargo Healthcare Conference — September 8 in Boston, MA Fireside chat at 3:45 pm ET Citi’s Biopharma Back to School Summit — September 9 in New York, NY Fireside chat at 3:40 pm ET Learn more: ir.zymeworks.com/events-and-…

As we recognize Ovarian Awareness Month, we’re highlighting our ongoing work to explore new approaches for patients with difficult-to-treat gynecological cancers. In June, we shared new clinical findings from the Phase 1 study of our folate receptor alpha (FRα)-targeting antibody-drug conjugate at the ESMO Gynaecological Cancers Congress. Among response-evaluable patients with platinum-resistant ovarian cancer, the investigational therapy demonstrated anti-tumor activity across both FRα-positive and FRα-negative tumors, reinforcing the potential of this approach. Zymeworks is currently evaluating strategic partnering opportunities to support the continued development of this program and maximize its long-term potential. Learn more about the clinical findings: lnkd.in/e_iKFMyv #OvarianCancerAwarenessMonth #OvarianCancer #GynecologicCancers #ADC #CancerResearch

September is Ovarian Cancer Awareness Month — a time to recognize the patients, families and communities affected by these cancers and to raise awareness of the signs, symptoms and resources available to those seeking information and support. Early symptoms of ovarian and other gynecologic cancers can sometimes be difficult to recognize or may be mistaken for other conditions. We encourage anyone looking to learn more to explore resources from the American Association for Cancer Research, including information about ovarian cancer, treatment options and resources for patients and caregivers: aacr.org/patients-caregivers… #OvarianCancerAwarenessMonth #GynecologicCancers #OvarianCancer

Today, we recognize Women’s Equality Day — an opportunity to celebrate the progress made toward gender equality and recognize the work that continues to ensure women have equal opportunities to lead, contribute and make an impact. At Zymeworks, we’re proud to celebrate the women across our organization whose expertise, leadership and contributions help advance science and make a difference for patients. #WomensEqualityDay #WomenInScience #GenderEquality

The latest approval of Ziihera® (zanidatamab-hrii) for first-line HER2-positive gastroesophageal adenocarcinoma (GEA) marks another important milestone for a medicine discovered and engineered by Zymeworks using our proprietary Azymetric™ platform. Together with our partners, we’re proud to see zanidatamab bring a new treatment option to more patients with difficult-to-treat cancers. Read the press release: ir.zymeworks.com/news-releas…